Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 10:20pm CEST

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
[email protected]

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HALOZYME THERAPEUTICS, INC
09/21 BRISTOL MYERS SQUIBB : and Halozyme Enter Global Collaboration and License Agree..
09/21 HALOZYME THERAPEUTICS : Licenses New Enhanze Target For $30 Million Upfront Paym..
09/15 HALOZYME THERAPEUTICS, INC. : Today's Research Reports on Stocks to Watch: Haloz..
09/15 BIOTECH MOVERS : Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) and Halozyme Ther..
09/15 Halozyme signs mammoth drug partnerships
09/14 HALOZYME THERAPEUTICS : Rockets on Bristol-Myers Deal
09/14 HALOZYME THERAPEUTICS : Increases 2017 Financial Guidance
09/14 HALOZYME THERAPEUTICS : Licenses New Enhanze Target For $30 Million Upfront Paym..
08/28 HALOZYME THERAPEUTICS : to Present at Upcoming Healthcare Conferences
08/25 HALOZYME THERAPEUTICS : To Present At Upcoming Healthcare Conferences
More news
News from SeekingAlpha
09/21 HALOZYME THERAPEUTICS : Updates To Thesis
09/16 Faison's Weekend Review And Scans
09/14 Midday Gainers / Losers
09/14 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
09/14 PREMARKET GAINERS AS OF 9 : 05 am